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6-Deoxy-6-fluorogalactofuranosides: regioselective glycosylation, unexpected 
reactivity, and anti-leishmanial activity 
Jeane Vaugenot,a Abderrafek El Harras,a Olivier Tasseau,a Rémi Marchal,a Laurent Legentil,a Boris Le Guennic,a Thierry 
Benvegnu,a and Vincent Ferrières*a
Selective glycosylation of the C-6 fluorinated galactofuranosyl acceptor 2 was studied with four galactofuranosyl donors. It was highlighted that this 
electron-withdrawing atom strongly impacted the behavior of the acceptor, thus leading to unprecedented glycosylation pathways. Competition between 
expected glycosylation of 2, ring expansion of this acceptor and furanosylation, and intermolecular aglycon transfer was observed. Further investigation of 
the fluorinated synthetic compounds showed that the presence of fluorine atom contributed to increase the inhibition of the growth of Leishmania 
tarentolae, a non-pathogenic strain of Leishmania.
Introduction 
The effects of fluorine atom, known to influence biological 
properties,1-6 are mainly correlated with its physicochemical 
properties.7-9 Due to its size and to the presence of non-binding 
doublets, it can interestingly mimic hydroxyl group. However, its 
strong electronegativity is also responsible for changes in charge 
distribution along covalent links. As an example, the substitution of 
OH group at C-2 or C-5 of glycosyl entities was deeply studied by 
the Withers10 and Wong11, 12 laboratories. The electron-withdrawing 
effect of fluorine at the proper position strengthens the anomeric 
bond, so that inhibiting properties were established. More recently, 
the impact of the presence of fluorine atoms on the carbohydrate 
conformation,s13, 14 even on glycosyl cation,15 and was studied. 
Moreover, fluorine-containing carbohydrates were used to improve 
immune response16 or as molecular tools to study interactions with 
lectins,17-19 or to trap the covalent glycosyl-enzyme intermediates.20 
Similar reactive species were observed thanks to the substitution of 
NHAc group by F atom.21 The contribution of this halogen has also 
been of great help in elucidating the ring contraction of 
galactopyranose (Galp) into the less stable galactofuranose (Galf) 
form in the corresponding nucleotide-sugars. Such rare behavior is 
now well documented and is catalyzed by UDP-Galp mutases.22, 23 In 
order to elucidate this mechanism, the galactopyranose moiety of 
the natural substrate (UDP-Galp) was fluorinated at positions 2,24, 25 
3,25 and 4.26 The 6-hydroxyl group of the pyranose form was also 
substituted by fluorine to study another family of important 
enzymes, the galactopyranosyl transferases.27 More recently, 
substrates initially present in the furanose form were also prepared: 
the 2,2,3,3-tetra-fluoro-derivative, able to enhance affinity for the 
mutase and so to inhibit its activity,28, 29 and the primary 
monofluoro-analog.30 With this latter structural modulation, 
inhibition of both mutase and transferases, required in 
Mycobacterium tuberculosis for the biosynthesis of the natural 
polygalactofuranoside and the survival of the pathogen, was 
observed.30, 31 As another consequence, weaker nucleophilicity of 
the vicinal OH-5 was anticipated, so that ring expansion was left 
aside, thus resulting in increased stability of UDP-6-F-Galf. 
Alongside these studies, fluoro-derived furanosides were 
further used as substrates in transglycosylation reactions catalyzed 
by a furanosyl hydrolase.32 Several di- and trisaccharides were 
isolated and their ability to induce production of TNF-α by murine 
macrophages was demonstrated, thus opening interesting 
opportunity in the field of immunostimulation. Amongst the 
oligofuranosides obtained, the disaccharide 1 (Sch. 1), characterized 
by the presence of a lipid chain on the reducing moiety, two 
fluorine atoms substituting both primary hydroxyls, and a β-(1→2)-
connection, showed promising activities. Moreover, in order to 
further demonstrate biological interests of furanosyl-containing 
derivatives,33 we have also demonstrated that alkyl furanosides are 
able to inhibit the growth of Leishmania, a parasite infecting 1 to 2 
million people annually.34 Such simple monosaccharides indeed 
impair the parasite by rigidifying and so disturbing its membrane.35  
 
 
 
Sch. 1 Retrosynthetic scheme. 
This study describes firstly the chemical approach towards 1 
starting from the known fluorinated galactofuranosidic acceptor 
2.36 Considering the 6-F function, we expected that electron-
withdrawing property of the halogen atom, which dissipates with 
distance, may result in reactivity for OH-2 slightly better than the 
one of OH-3, but clearly improved with respect to that of OH-5. 
Therefore, it was envisaged not to use protecting groups, thus 
saving time-consuming manipulations. Moreover, this acceptor was 
a good model compound to study possible regioselective 
glycosylation, a research field explored in pyranose series37, 38 but 
scarcely in the furanose one.39, 40 Finally, the second partner of the 
coupling, donor 3, was designed with participating benzoyl group 
on C-2 to ensure β-configuration. Since it is fluorinated at C-6, it 
was obtained from 4,41 a building block useful to prepare 2, thus 
making the strategy highly convergent. Secondly, leishmanicidal 
effect was also evaluated on Leishmania tarentolae, the non-
pathogenenic strain of Leishmania spp., for some synthesized neo-
octyl digalactofuranosides. 
Results and discussion 
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The synthesis of acceptor 2 and donors 3 (Sch. 2) started from 
known building block 4 through a regioselective opening of the 
cyclic sulfate by fluoride anion to give 5 in 84% yield. While 
Zemplén debenzoylation afforded 2, acido-catalyzed acetolysis 
gave 6 which was isolated as an anomeric mixture in 81% yield. 
Subsequent bromination and thioglycosylation gave donors 3a 
and 3b, respectively, both in 91% yields. 
Sch. 2 Synthesis of studied acceptor 2 and donors 3. 
Regioselective glycosylation of 2 was then performed 
(Table 1). With brominated donor 3a under activation by 
silver(I) trifluoromethanesulfonate (AgOTf), three products 
were chromatographically isolated. Mass spectrometry (MS) 
data suggested the presence of a disaccharide (7) and two 
monosaccharides (8, 9) (entry 1). Compound 8 resulted from 
partial hydrolysis of donor 3a. The second monosaccharide 9 
was characterized by monoisotopic footprint (m/z=567.2365), 
1H NMR signals between 1 and 2 ppm, a primary carbon at 
80.6 ppm with a coupling constant of 173 Hz, and three signals 
corresponding to carbonyl functions (170.1, 165.6 and 165.4 
ppm). These are evidence of the presence of fluorine atom and 
of an aliphatic chain. Moreover, δC-1 at 105.6 ppm attested a 
sugar residue in a furanose form. This was corroborated by a 
low JH1,H2, also synonymous of a β configuration. It results from 
these analytical data that the peracylated 6-fluorinated octyl 
galactofuranoside 9 was obtained during the coupling 
reaction. This suggests an apparent intermolecular transfer of 
aglycon from the acceptor 2 to the donor 3a. 
Considering now the structure of the disaccharide 
(m/z=731.2847), expected signals for the furanosidic entity (δC-
1b=108.0 ppm, JH1b,H2b=3.2 Hz) allowed to identify the non-
reducing moiety (b). The reducing residue (a) was 
characterized by HMBC thanks to chemical shift for C-1a at 
98.4 ppm and a coupling constant JH1a,H2a of 3.6 Hz. Moreover, 
correlation between H-1b (5.07 ppm) and C-5b (68.5 ppm) 
gave evidence for a six-membered ring. Finally, a high chemical 
shift for C-2a (78.3 ppm) and a correlation between C-1b 
(108.3 ppm) and H-2a (3.89 ppm) led to the structure β-D-Galf-
(1→2)-α-D-Galp for 7, thus revealing isomerization of the 
furanosidic acceptor. 
On the basis of this result, subsequent attempt was 
performed in the presence of molecular sieves (entry 2) in 
order to avoid ring expansion of the unprotected acceptor. 
Even if furanosides 8 and 9 were still isolated in non-negligible 
amounts, the desired disaccharides 10 and 11 were both 
isolated in 8% yields. For these compounds, the furanose form 
of the reducing moiety was clearly established thanks to high 
δ-values measured for C-1a (106.1 and 108.0 ppm), and JH1a,H2a 
lower than 1 Hz. Since glycosylation also shifts signal for the 
carbon centre involved in the new bond towards high fields, 
this resulted in sequences β-D-Galf-(1→2)-β-D-Galf (10) and β-
D-Galf-(1→3)-β-D-Galf (11). Surprisingly, the analysis of this 
complex mixture underlined the presence of another 
disaccharide isolated in similar ratio, i.e. the β-D-Galf-(1→5)-β-
D-Galf (12). This structure was deduced from characteristic 
data [JH1b,H2b near 1 Hz for H-1b, 107.9 and 106.4 ppm for C-1a 
and C-1b, respectively, and 75.6 ppm for C-5a, as well as 
correlation from HMBC spectrum between H-5a (4.33 ppm) 
and C-1b (106.4 ppm)]. As a consequence, all three hydroxyl 
groups in acceptor 2 appeared to have reacted to a similar 
extend. 
When 2 reacted with 3b (entry 3) under the assistance of 
N-iodosuccinimide (NIS) and trimethysilyl triflate (TMSOTf), a 
complex mixture was obtained from which the trisaccharide 13 
(m/z=1145.3971) could be isolated. As previously, the furanose 
configuration for the non-reducing parts was unambiguously 
established. Otherwise, the acceptor also underwent a ring 
expansion leading to the β-D-Galf-(1→2)-[ β-D-Galf-(1→3)]-α-
D-Galp skeleton for 13 (δC-1p=98.7 ppm vs. δC-1f=107.3 and 
107.6 ppm). Decreasing the reaction temperature to -30 °C 
(entry 4) allowed synthesizing the same trisaccharide as well as 
the disaccharides 7 and 14. Chemical shifts for 14 (δC-1a=98.5 
ppm, δC-1b’=107.3 ppm, δC-3a=78.0 ppm) were characteristic for 
a β-D-Galf-(1→3)-α-D-Galp arrangement, a regioisomer of 7. In 
order to avoid the furanose-pyranose isomerization, attempts 
with lower amount of Lewis acid catalyst were performed at 0 
or -50 °C (entries 5 and 6). Under these conditions, di- and 
trisaccharides were isolated in moderate overall 22% and 36% 
yields, respectively. Fortunately, no pyranosyl entity was 
detected. The desired β-D-Galf-(1→2)-β-D-Galf 10 and β-D-
Galf-(1→3)-β-D-Galf 11, as well as the β-D-Galf-(1→5)-β-D-Galf 
12 were obtained. A mixture of trisaccharides 15 (MS found 
1145.3969) was also synthesized. 
Table 1 Glycosylation of acceptor 2 by donor 3. 
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 [a] The reaction was performed with molecular sieves. [b] Structures of isolated and characterized products. [c] Ratio was deduced 
from 1H NMR spectra 
Considering the moderate yields of the reactions reported 
in Table 1, further glycosylations of acceptor 2 were performed 
using the non-fluorinated donors42 16a and 16b (Table 2). 
These substrates afforded products in much more interesting 
overall 95% and 78% yields, respectively (entries 1 and 4). 
Once again, coupling with brominated donor mainly gave side-
products resulting from hydrolysis (18, 43%) and apparent 
transglycosylation (19, 45%). Moreover, preservation of the 
five-membered ring size of the acceptor was better performed 
with thioglycoside 16b (entry 4) than with 16a (entry 1). 
Finally, the desired (1→2)- (20) and (1→3)- (21) disaccharides 
were obtained, still with the (1→5)-isomer (22). A mixture of 
trisaccharides 23 was also obtained (m/z 1473.4891) but exact 
structure could not be elucidated. 
Even if far away from the electrophilic or nucleophilic 
centres, the fluorine atoms on the furanosyl donors and 
acceptor significantly impacted the progress of the reaction. 
Considering firstly the donors, this study clearly showed a 
lower reactivity of the fluoro-compounds 3 compared to the 
non-fluorinated donors 16. Secondly, from the unprotected 
acceptor, ring expansion indicated a non-negligible 
nucleophilicity for OH-5, and hydrogen bonding cannot be 
excluded. 
The transfer of the O-aglycon from the acceptor towards 
the donor constituted an unexpected second side-reaction. 
The stability of 2 was thus studied under glycosylation 
conditions but in the absence of donor. Even in the presence 
of a large amount of water (0.5 equiv.), neither the octanol 
release nor the formation of the thermodynamically more 
stable α-pyranosidic counterpart was observed. In other 
words, none of the electrophilic species, i.e. silver cation, 
iodonium ion, the Lewis acid TMSOTf, possibly the proton, may 
induce transformation of the furanosidic acceptor 2. That 
suggests that interactions with the activated donor (Sch. 3) 
induced competitive behaviour: glycosylation leading to Galf-
Galf disaccharides, but also weakening of bonds involving the 
anomeric centre. The latter phenomenon resulted in 
transglycosylation when C-1–O-1 of the acceptor 2 was 
broken, or in Galf-Galp formation through C-1–O-4 cleavage 
and glycosylation. 
Table 2 Glycosylation with non-fluorinated donors 16. 
Entry Donor Promotor 
(equiv.) 
T 
(°C) 
Products (yield) 
1 16a AgOTf (1) 20 17 (7%), 18 (43%), 19 
(45%) 
2 16a AgOTf (1) 20 17 (42%), 19 (2%), 20 
(7%), 21 (5), 22 (10%)a 
Entry Donor Promotor (equiv.) T (°C) Products (yield)[b] 
1 3a AgOTf (1) 20 7 (8%), 8 (22%), 9 (45%) 
2[a] 3a AgOTf (1) 20 10 (8%), 11 (8%), 12 (11%), 8 (15%), 9 (20%) 
3 3b NIS (2.3), TMSOTf (1.2) 0 13 (11%) 
4[c] 3b NIS (2.3), TMSOTf (1.2) - 30 7 (6%), 14 (6%), 13 (11%) 
5 3b NIS (2.3), TMSOTf (0.5) 0 10 (7%), 11 (5%), 12 (1%), Trifuranosides 15 (9%) 
6 3b NIS (2.3), TMSOTf (0.5) - 50 10 (12%), 11 (5%), 12 (9%), Trifuranosides 15 (11%) 
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3 16a AgOTf (1) -50 18 (49%), 19 (8%), 20 
(7%), 21 (4%), 22 (9%)a 
4b 16b NIS (2.3), 
TMSOTf 
(0.5) 
-50 20 (6%), 21 (5%), 22 
(10%), 23c (57%)d 
[a] 20-22 ratio was estimated by 1H NMR; [b] Non-separable 
mixture of di- and trisaccharides; [c] Exact structure of the 
trisaccharide could not be obtained; [d] Conversion yield 
calculated from acceptor 2. 
 
These experimental results from acceptor 2 also gave 
evidence that a non-negligible nucleophilicity remained for 
both OH-5 and O-1. The influence of fluorine atom on the 
acceptor reactivity was previously studied, but neither on 
glycosidic acceptors nor on furanosyl derivatives.43 The O-1 
(from 2) reactivity observed herein, reminded us of the 
secondary reaction often observed during the glycosylation of 
a thioglycoside used as an acceptor with a brominated 
donor.44 This is generally explained by the residual 
nucleophilicity of the Sulphur atom. 
 
 
 
 
 
 
Sch. 3 Possible interactions that may explain experimental 
results. 
 
A computational approach based on Density Functional 
Theory (see Computational details) was considered in order to 
decipher our observations. The methyl glycosides were used as 
model compounds in order to limit calculation time. Assuming 
first a kinetically controlled reaction, condensed Fukui 
functions were considered. They describe the electron density 
after adding or removing electrons, and thus are suitable for 
predicting where the most electrophilic and nucleophilic sites 
on a molecule are.45 Since calculations depend on the overall 
conformation, and considering the flexibility of the furanose 
rings in solution,46, 47 two conformations of the methyl β-D-
galactofuranoside, 4TO and 
3T2 for conformers A and B, 
respectively, were optimized. Among several hypothetic 
starting structures that were optimized, only these two 
conformations were minima on the potential energy surface as 
confirmed by frequency calculations. They mainly differ by the 
orientation of the C-4–C-5–C-6 side arm carrying the halogen 
atom (Fig. 1). They are almost iso-energetic with conformer A 
slightly more stable than conformer B by 0.03 eV at the 
B3LYP/6-311G(d) level of calculations, while the opposite is 
found with the M06-2X functional (see ESI). 
 
 
 
 
 
 
 
Fig. 1 DFT optimized structures for the two conformers at the 
B3LYP/6-311G(d) level. Colors: Carbon: grey; Oxygen: red; 
Fluorine: blue. 
 
Furthermore, f- values obtained for all oxygen atoms (Table 
3) showed that nucleophilicity is significantly higher for O-1 
than for all other oxygen atoms, whatever the population 
analysis scheme (Mulliken, Hirshfeld, Voronoi, or Bader) or the 
functional used. This result was quite relevant for supporting 
the transfer of the O-aglycon to the donor. Moreover, O-2 and 
O-3 appeared to have similar nucleophilicity, and (1→2)- and 
(1→3)-disaccharides were indeed isolated in very close 
proportions. Fukui values, however, appear to be 
inappropriate for explaining the observed reactivity of O-5. 
Nevertheless, the H-bond donating ability of OH-5 due to the 
vicinal fluorine atom,48 whatever the solvent used, could 
increase the reactivity of O-5. 
On another hand, the process could also be governed by 
thermodynamic factors. We therefore evaluated the energy 
difference between products 7 [β-D-Galf-(1→2)-α-D-Galp] and 
10 [β-D-Galf-(1→2)-α-D-Galf] in their methyl version, and using 
the same procedure as previously described. As expected, the 
pyranosyl-containing disaccharide 7 was significantly more 
stable than its difuranosyl isomer 10 (∆E=0.47 eV). 
Consequently, based on this computational inspection, it is not 
possible to decide between thermodynamic or kinetic control 
for the studied glycosylation reaction but both are convergent 
and could contribute to explain the main experimental results 
obtained, i.e. the ring expansion and the aglycon transfer.
 
Table 3 Calculated condensed atomic Fukui functions f- for different atomic charges at the B3LYP/6-311G(d) level. 
 Conformation A Conformation B 
 Mullikena Hirshfeld Voronoi Bader Mullikena Hirshfeld Voronoi Bader 
O-1 0.18 0.17 0.19 0.26 0.19 0.18 0.20 0.32 
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  5 
O-2 0.11 0.11 0.10 0.07 0.09 0.09 0.08 0.03 
O-3 0.09 0.09 0.08 0.10 0.10 0.10 0.10 0.12 
O-4 0.04 0.04 0.04 -0.02 0.05 0.04 0.05 0.03 
O-5 0.03 0.03 0.03 0.02 0.02 0.02 0.02 0.01 
Finally, debenzoylation under Zemplén conditions afforded 
pure difluorinated disaccharides 24-27 and a mixture of non-
separable disaccharides 28-30 (Fig. 2). It is interesting to note 
that the difuranoside 24 presents the same NMR 
characteristics as the product previously obtained thanks to a 
biocatalyzed approach.32 The chemical approach also afforded 
new disaccharides 25-30 and thus complements well the 
chemoenzymatic synthesis. 
Fig. 2 Structures of deprotected compounds (yield of 
deacylation). 
It was previously demonstrated that octyl galactofuranoside 
derivatives with polar substituent at C-6 position showed 
promising parasitostatic activities against the promastigote 
form of Leishmania donovani.35 Therefore, the growth of 
Leishmania tarentolae, the non-pathogenic analog, was further 
investigated in the presence of the octyl 6-fluoro Galf 2 and 
the synthetic difuranosides 24, 28-30, 27, and 26. Their 
activities were compared to the ones of the non-fluorinated 
and 6-fluorinated octyl monogalactofuranosides, GalfOct and 
2, respectively. The minimum inhibition concentration (MIC), 
responsible for 99% of parasite growth inhibition, was 
calculated on L. tarentolae with increasing concentrations of 
the studied octyl glycosides. The reference GalfOct had a MIC 
value of 0.75 mM. While disaccharide 27, bearing two fluorine 
atoms and a pyranosidic residue, did not show activity at a 
concentration of 1 mM, disaccharides 27 and 28-30, 
characterized by the presence of non-fluorinated Galf non-
reducing end, demonstrated similar activity as the GalfOct 
(0.75 mM). Lower MIC values were obtained for the 
disaccharides 26 (0.5 mM), 24 (0.25 mM) and the 
monosaccharide 2 (0.175 mM), all presenting an external 6-
deoxy-6-fluoro Galf entity. These results highlighted the 
beneficial effect of fluorination on furanosyl entities at the 
non-reducing end, provided that the carbohydrate linked to 
the alkyl chain is not in the pyranose form. The latter 
observation can be correlated to the absence of leishmanicidal 
activity of octyl galactopyranoside on the infectious parasite 
Leishmania donovani.35 
Experimental 
General Experimental Details. Reagents were purchased from 
commercial sources and were used without further, except 
octyl galactofuranoside.49 Dried dichloromethane was 
purchased sealed. All reactions were monitored by TLC on 
Silica Gel 60 F254, and spots were detected under 254 nm UV-
light and/or by staining with orcinol solution. Column 
chromatography was performed on Silica Gel (25 or 50 μm). 
NMR spectra were recorded at 400 MHz for 1H and 100 MHz 
for 13C. Chemical shifts are given in δ units (ppm) and 
referenced to either CDCl3 or CD3OD. Coupling constants J 
were calculated in Hertz (Hz). Proton and carbon NMR peaks 
were unambiguously assigned by COSY (double quantum 
filtered with gradient pulse for selection), HSQC (gradient 
echo−antiecho selection and shape pulse) and HMBC 
(echo−antiecho gradient selection, magnitude mode) 
correlation experiments. For each isolated compound, the 
reducing end was quoted as “a”, and nonreducing entity as 
“b”. High Resolution Masses were recorded in positive mode 
using direct Electrospray ionization on a Brucker maXis 4G or a 
Thermo Fisher Q-Exactive spectrometer. 
n-Octyl 2,3-di-O-benzoyl-6-deoxy-6-fluoro-β-D-galactofuranoside 
(5). To a solution of 441 (550 mg, 0.98 mmol) in acetone (5.5 mL) 
was added a 1 M solution of TBAF in THF (1.5 mL, 1.5 mmol). After 
stirring at room temperature for 1 h and concentration under 
reduced pressure, the crude oil was diluted in THF (5.5 mL) before 
adding a solution of concentrated aqueous H2SO4 (152 µL, 2.7 
mmol) and H2O (48.6 µL, 2.7 mmol). The reaction media was stirred 
at room temperature for 20 min and then neutralized with Et3N, 
concentrated under reduced pressure and partitioned between 
AcOEt (25 mL) and brine (7 mL). The organic layer was washed with 
aqueous saturated Na2CO3 solution and the aqueous layers 
extracted with AcOEt (3x5 mL). The combined organic layers were 
dried over MgSO4, filtered and concentrated under reduced 
pressure. Flash chromatography (Chex/AcOEt gradient from 100:0 
up to 50:50) afforded the desired product as a colorless oil (414 mg, 
84%); Rf=0.3 (Chex/AcOEt 5:1); 1H NMR (CDCl3): 8.11-8.03 (m, 4H, 
Harom), 7.63-7.55 (m, 2H, Harom), 7.50-7.40 (m, 4H, Harom), 5.59 (ddd, 
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J3,4=4.5 Hz, J2,3=1.3 Hz, J1,3=0.7 Hz, 1H, H-3), 5.51 (d, J2,3=1.3 Hz, 1H, 
H-2), 5.26 (s, 1H, H-1), 4.68-4.46 (m, 1H, H-6a), 4.40-4.27 (m, 1H, H-
6b), 4.39-4.29 (m, H-4, H-5), 3.74 (dt, 2J=9.5 Hz, 3J=6.8 Hz, 1H, 
OCH2), 3.53 (dt, 
2J=9.5 Hz, 3J=6.2 Hz, 1H, OCH2), 1.6 (m, 2H, 
OCH2CH2), 1.27 (m, 10H, 5 CH2), 0.86 (t,
3J=6.8 Hz, 3H, CH3); 
13C NMR 
(CDCl3): 166.3 (CO), 165.5 (CO), 133.7, 130.1, 130.0, 129.2, 129.2, 
128.7, 128.6 (C6H5), 105.8 (C-1), 83.8 (d, JC6-F=171.4 Hz, C-6), 82.5 (d, 
JC4-F=5.2 Hz, C-4), 81.5 (C-2), 78.0 (d, JC3-F=1.4 Hz,C-3), 69.4 (d, JC5-
F=20.4 Hz, C-5), 67.8 (OCH2), 32.0 (OCH2CH2), 29.5, 29.4, 27.1, 26.3, 
22.8 (5 CH2), 14.2 (CH3); HRMS: Calcd for C28H36O8FNa [M+Na]
+ 
523.2302; found 523.2301. 
 
1,5-di-O-Acetyl-2,3-di-O-benzoyl-6-deoxy-6-fluoro-D-
galactofuranose (6). To a solution of 6 (150 mg, 0.28 mmol) in dry 
CH2Cl2 (1.5 mL) were added acetic anhydride (170 µL, 1.8 mmol) 
and sulfuric acid (31.5 µL, 0.58 mmol). The mixture was stirred 6 h 
at room temperature and then neutralized with Et3N. CH2Cl2 (10 
mL) was added to the mixture and washed with aqueous saturated 
NaHCO3 solution (3x6 mL) and aqueous saturated NaCl solution 
(2x7 mL, until pH 7). Organic layer was dried over MgSO4 and 
concentrated under reduced pressure. Flash chromatography 
(CHex/AcOEt gradient from 100:0 up to 60:40) afforded 6 (108 mg, 
81%, α/β=16:84) as a colourless oil. Rf=0.5 (CHex/AcOEt 7:3); Data 
for 6β: 1H NMR (CDCl3): 8.15-7.97 (m, 4H, Harom), 7.69-7.55 (m, 2H, 
Harom), 7.54-7.43 (m, 4H, Harom), 6.45 (s, 1H, H-1), 5.59 (d, J2,3=1.4 Hz, 
1H, H-2), 5.58-5.50 (m, 2H, H-3, H-5), 4.78-4.69 (m, 1H, H-6a), 4.66-
4.56 (m, 2H, H-6b, H-4), 2.18 (s, 3H, OCH3), 2.04 (s, 3H, OCH3); 
13C 
NMR (CDCl3): 170.1 (CO), 169.2 (CO), 165.5 (CO), 165.3 (CO), 134.0, 
133.9, 130.1, 130.0, 129.0, 128.8, 128.7 (C6H5), 99.3 (C-1), 82.3 (d, 
JC4-F=5.1 Hz, C-4), 81.1 (C-3), 80.9 (d, JC6-F=173.5 Hz, C-6), 76.9 (C-2), 
70.2 (d, JC5-F=20.9 Hz, C-5), 21.2 (CH3), 20.9 (CH3); HRMS : Calcd for 
C24H23O9FNa [M+Na]
+ 497.1218; found 497.1221. 
 
5-O-Acetyl-2,3-di-O-benzoyl-6-deoxy-6-fluoro-β-D-
galactofuranosyl bromide (3a). To a solution of 6 (300 mg, 0.63 
mmol) in glacial acetic acid (2.2 mL) was added hydrogen bromide 
30% in acetic acid (250 µL, 1.3 mmol). The mixture was left under 
agitation at room temperature for 3 h. CH2Cl2 (10 mL) was added 
and the mixture was washed with aqueous iced water (2x5 mL) and 
aqueous iced saturated NaHCO3 solution (2x5 mL). The organic layer 
was dried over MgSO4 and concentrated under reduced pressure to 
afford 3a (340mg) in 91% yield as a beige solid. 1H NMR (CDCl3): 
8.15-8.10 (m, 2H, Harom), 8.08-8.04 (m, 2H, Harom), 7.66-7.58 (m, 2H, 
Harom), 7.52-7.45 (m, 4H, Harom), 6.59 (d, J1,2=1Hz, 1H, H-1), 5.88 (d, 
J1,2=0.7 Hz, 1H, H-2), 5.67 (dq, J5,F=17.2 Hz, J4,5=4.9 Hz, 1H, H-5), 5.53 
(dt, J3,4=4.5 Hz, J2,3=0.9 Hz, 1H, H-3), 4.80 (td, J3,4=4.6, 0.8 Hz, 1H, H-
4), 4.67 (dt, J6,F=46.5 Hz, J6a,6b=5.2 Hz, 2H, H-6), 2.08 (s, 3H, OCH3); 
13C NMR (CDCl3): 169.9 (CO), 165.5 (CO), 165.0 (CO), 134.0, 133.9, 
130.1, 129.9, 128.7 (C6H5), 87.9 (C-1), 85.3 (C-2), 83.7 (d, JC4-F=5.2 
Hz, C-4), 80.8 (d, JC6-F=174.3 Hz, C-6), 76.3 (C-3), 69.5 (d, JC5-F=21.1 
Hz, C-5), 20.7 (OCH3); HRMS: Calcd for C22H20O7FBr Na [M+Na]
+ 
517.0269; found 517.0260. 
 
Thiophenyl 5-O-acetyl-2,3-di-O-benzoyl-6-deoxy-6-fluoro-β-D-
galactofuranoside (3b). To a solution of 6 (40 mg, 0.08 mmol) in dry 
CH2Cl2 (0.20 mL) at -5 °C, were added thiophenol (13 µL, 0.12 mmol) 
and BF3.Et2O (10.6 µL, 0.095 mmol). The mixture was left stirring at 
room temperature for 2 h. CH2Cl2 (10 mL) was added and the 
mixture was quickly washed with iced water (2x5 mL) and aqueous 
iced saturated NaHCO3 solution (2x5 mL). The organic layer was 
dried over MgSO4 and concentrated under reduced pressure. Flash 
chromatography (CHex/AcOEt gradient from 100:0 up to 90:10) 
afforded 3b (38 mg, 91%) of the desired product as white foam. 1H 
NMR (CDCl3): 8.14-8.00 (m, 4H, Harom), 7.67-7.54 (m, 4H, Harom), 
7.53-7.42 (m, 4H, Harom), 7.38-7.27 (m, 3H, Harom), 5.77 (br s, 1H, H-
1), 5.65 (d, J2,3=1.6 Hz, 1H, H-2), 5.64-5.51 (m, 2H, H-5, H-3), 4.77 (t, 
J=4.8 Hz, 1H, H-4), 4.75-4.68 (m, 1H, H-6a), 4.65-4.55 (m, 1H, H-6b), 
2.08 (s, 3H, OCH3); 
13C NMR (CDCl3): 170.3 (CO), 165.6 (CO), 165.4 
(CO), 133.9, 133.8, 133.3, 132.7, 130.2, 130.0, 129.2, 129.0, 129.0, 
128.7, 128.7, 128.2 (C6H5), 91.3 (C-1), 82.2 (C-2), 81.2 (d, JC6-F=172.4 
Hz, C-6), 80.4 (d, JC4-F=5.2 Hz, C-4), 77.4 (d, JC3-F=1 Hz, C-3), 70.1 (d, 
JC5-F=20.9 Hz, C-5), 20.9 (OCH3); HRMS: Calcd for C28H25O7FNa 
[M+Na]+ 547.1197; found 547.1198. 
 
Glycosylation of acceptor 2 from brominated donors (A): To a 
solution of the acceptor 2 in dry acetonitrile (75 mM) was added a 
spoon of previously activated molecular sieves 4 Å. The mixture was 
left under agitation for 30 min. Donor and then AgOTf were added 
to the flask and the mixture was stirred at the desired temperature 
for 2 h. The reaction was quenched by adding Et3N and silver salts 
were filtered over celite. Solvent was removed under reduced 
pressure. Flash chromatography (Chex/AcOEt 100:0 up to 0:100) 
afforded the different products. Yields are given in tables 1 and 2. 
 
Glycosylation of acceptor 2 from thioglycosides (B): To a solution 
of the acceptor 2 in dry CH2Cl2 (0.2 M) were added NIS (2.3 equiv) 
and TMSOTf. The mixture was stirred for 10 min. In another flask, of 
the thiofuranosidic donor (1.2 equiv.) was dissolved in dry CH2Cl2 
(0.2 M). The acceptor was put at the desired temperature and the 
donor solution was added. The mixture was then stirred for 2 h. The 
reaction was quenched with NaHCO3 and solvent was removed 
under reduced pressure. Flash chromatography (Chex/AcOEt 100:0 
up to 0:100) afforded the different products. Yields are given in 
tables 1 and 2. 
 
Octyl 5-O-acetyl-2,3-di-O-benzoyl-6-deoxy-6-fluoro-β-D-
galactofuranosyl-(1→2)-6-deoxy-6-fluoro-α-D-galactopyranoside 
(7): Compound 7 was obtained according to procedure A (table 1, 
entry 1) and procedure B (table 1, entry 4) and isolated as a white 
solid. Rf=0.2 (CHex/AcOEt, 6:4); NMR data in tables 4 and 5. 1H 
(CDCl3): 8.10-8.03 (m, 4H, Harom), 7.63-.57 (m, 2H, Harom), 7.50-7.43 
(m, 4H, Harom), 3.73 (dt, 
2J=9.7 Hz, 3J=6.9 Hz, 1H, OCH2), 3.47 (dt, 
2J=9.7 Hz, 3J=6.6 Hz, 1H, OCH2), 2.08 (s, 3H, OCH3), 1.65-1.48 (m, 2H, 
OCH2CH2), 1.36-1.12 (m, 10H, 5 CH2), 0.86 (t,
3J=7.2 Hz, 3H, CH3); 
13C 
NMR (CDCl3): 170.1 (CO), 166.5 (CO), 165.7 (CO), 134.0, 133.9, 
130.2, 130.1, 128.9, 128.8, 128.7, 128.6 (C6H5), 68.8 (OCH2), 32.0 
(OCH2CH2), 29.7, 29.5, 29.3, 26.4, 22.8 (5 CH2), 20.9 (OCH3), 14.2 
(CH3). HRMS: Calcd for C36H46O12F2Na [M+Na]
+ 731.2849; found 
731.2847. 
 
5-O-Acetyl-2,3-di-O-benzoyl-6-deoxy-6-fluoro-α,β-D-
galactofuranose (8): Compound 8 was obtained according to 
procedure A and isolated as a white solid (table 1, entries 1, 2). 
Rf=0.4 (CHex-AcOEt, 6-4); 1H NMR (CDCl3): 8.11-8.02 (m, 4H, Harom), 
7.63-7.56 (m, 2H, Harom), 7.49-7.41 (m, 4H, Harom), 5.65 (s, 1H, H-1), 
5.61-5.45 (m, 3H, H-2, H-3, H-5), 4.69 (t, J=4.7 Hz, 1H, H-4), 4.67 
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(ddd, J6a, 6b=46.7 Hz, J5,6=5.1 Hz, J5,6=1.7 Hz, 2H, H-6), 2.08 (s, 3H, 
OCH3); 
13C NMR (CDCl3): 170.2 (CO), 166.8 (CO), 166.6 (CO), 133.8, 
130.1, 130.0, 129.1, 129.0, 128.7 (C6H5), 101.1 (C-1), 82.4 (C-2), 81.1 
(d, JC6-F=176.3 Hz, C-6), 80.8 (d, JC4-F=3.2 Hz, C-4), 77.4 (C-3), 70.4 (d, 
JC5-F=20.7 Hz, C-5), 20.9 (OCH3). MS: Calcd for C22H21O8FNa [M+Na]
+ 
455.4; found 454.9. 
Octyl 5-O-acetyl-2,3-di-O-benzoyl-6-deoxy-6-fluoro-β-D-
galactofuranoside (9): Compound 9 was obtained according to 
procedure A as a white solid (table 1, entries 1, 2). Rf=0.9 
(CHex/AcOEt, 6:4) 1H NMR (CDCl3): 8.10-8.03 (m, 4H, Harom), 7.62-
7.56 (m, 2H, Harom), 7.49-7.43 (m, 4H, Harom), 5.57 (dq, J5,6a=16.9 Hz, 
J5,6b=5.0 Hz, 1H, H-5), 5.47-5.43 (m, 2H, H-2, H-3), 5.21 (s, 1H, H-1), 
4.70 (J=5.8 Hz, 10.0 Hz, 46.6 Hz, 1H, H-6), 4.64 (J=5.0 Hz, 10.0 Hz, 
46.6 Hz, 1H, H-6), 4.49 (t, J=4.5 Hz, H-4), 3.75 (dt, 2J=9.4 Hz, 3J=7.2 
Hz, 1H, OCH2), 3.53 (dt, 
2J=9.5, 3J=6.8 Hz, 1H, OCH2), 2.08 (s, 3H, 
OCH3), 1.69-1.57 (m, 2H, OCH2CH2), 1.44-1.01 (10H, 5 CH2), 0.86 (t, 
3J=6.5Hz, 3H, CH3); 
13C NMR (CDCl3): 170.1 (CO), 165.6 (CO), 165.4 
(CO), 133.6, 133.5, 129.9, 129.9, 129.2, 129.1, 128.5, 128.5 (C6H5), 
106.7 (C-1), 82.0 (C-2), 81.1 (d, JC6-F=173.2 Hz, C-6), 80.2 (d, JC4-F=5.7 
Hz, C-4), 77.3 (C-3), 70.4 (d, JC5-F=20.7 Hz, C-5) 67.7 (OCH2), 31.8 
(OCH2CH2), 29.5, 29.4, 29.3, 29.2, 22.7 (5 CH2), 20.8 (OCH3), 14.1 
(CH3). HRMS: Calcd for C30H37O8FNa [M+Na]
+ 567.2365; found 
567.2365. 
Octyl 5-O-acetyl-2,3-di-O-benzoyl-6-deoxy-6-fluoro-β-D-
galactofuranosyl-(1→2)-6-deoxy-6-fluoro-β-D-galactofuranoside 
(10): Compound 10 was obtained according to procedure A (table 1, 
entry 2) and procedure B (table 1, entries 5, 6) and isolated as a 
white solid. Rf=0.3 (CHex/AcOEt, 6:4); NMR data in tables 4 and 5. 
1H NMR (CDCl3): 8.09-8.03 (m, 4H, Harom), 7.64-7.57 (m, 2H, Harom), 
7.50-7.44 (m, 4H, Harom), 3.73 (dt, 
2J=9.5 Hz, 3J=6.8 Hz, 1H, OCH2), 
3.44 (dt, 2J=9.7 Hz, 3J=6.6 Hz, 1H, OCH2), 2.08 (s, 3H, OCH3), 1.62-
1.54 (m, 2H, OCH2CH2), 1.35-1.17 (m, 10H, 5 CH2), 0.88 (t,
3J=7.3 Hz, 
3H, CH3); 
13C NMR (CDCl3): 170.1 (CO), 166.7 (CO), 166.6 (CO), 
134.0, 133.9, 130.1, 130.0, 128.9, 128.8, 128.7, 128.7 (C6H5), 68.2 
(OCH2), 31.9 (OCH2CH2), 29.7, 29.4, 29.3, 26.2, 22.8 (5 CH2), 20.9 
(OCH3), 14.2 (CH3). HRMS: Calcd for C36H46O12F2Na [M+Na]
+ 
731.2849; found 731.2847. 
Octyl 5-O-acetyl-2,3-di-O-benzoyl-6-deoxy-6-fluoro-β-D-
galactofuranosyl-(1→3)-6-deoxy-6-fluoro-β-D-galactofuranoside 
(11): Compound 11 was obtained according to procedure A (table 1, 
entry 2) and procedure B (table 1, entries 5, 6) and isolated as a 
white solid. Rf=0.2 (CHex/AcOEt, 6:4); NMR data in tables 4 and 5. 
1H NMR (CDCl3): 8.08-8.02 (m, 4H, Harom), 7.63-7.56 (m, 2H, Harom), 
7.50-7.41 (m, 4H, Harom), 3.63 (dt, 
2J=9.5 Hz, 3J=6.9 Hz, 1H, OCH2), 
3.41 (dt, 2J=9.6 Hz, 3J=6.6 Hz, 1H, OCH2), 2.08 (s, 3H, OCH3), 1.59-
1.47 (m, 2H, OCH2CH2), 1.35-1.15 (m, 10H, 5 CH2), 0.86 (t,
3J=7.1 Hz, 
3H, CH3); 
13C NMR (CDCl3): 170.2 (CO), 166.7 (CO), 166.6 (CO), 
133.9, 133.8, 130.1, 130.0, 129.0, 128.9, 128.7, 128.6 (C6H5), 68.0 
(OCH2), 31.9 (OCH2CH2), 29.6, 29.4, 29.3, 26.1, 22.8 (5 CH2), 20.9 
(OCH3), 14.2 (CH3). HRMS: Calcd for C36H46O12F2Na [M+Na]
+ 
731.2849; found 731.2851. 
Octyl 5-O-acetyl-2,3-di-O-benzoyl-6-deoxy-6-fluoro-β-D-
galactofuranosyl-(1→5)-6-deoxy-6-fluoro-β-D-galactofuranoside 
(12): Compound 12 was obtained according to procedure A (table 1, 
entry 2) and procedure B (table 1, entries 5, 6) and isolated as a 
white solid. Rf=0.3 (CHex/AcOEt, 6:4); NMR data in tables 4 and 5. 
1H NMR (CDCl3): 8.12-8.03 (m, 4H, Harom), 7.63-7.55 (m, 2H, Harom), 
7.50-7.41 (m, 4H, Harom), 3.66 (dt, 
2J=9.7 Hz, 3J=6.7 Hz, 1H, OCH2), 
3.40 (dt, 2J=9.6 Hz, 3J=6.5 Hz, 1H, OCH2), 2.08 (s, 3H, OCH3), 1.58-
1.49 (m, 2H, OCH2CH2), 1.34-1.19 (m, 10H, 5 CH2), 0.88 (t,
3J=6.7 Hz, 
3H, CH3); 
13C NMR (CDCl3): 170.2 (CO), 166.8 (CO), 166.4 (CO), 
133.9, 133.8, 130.3, 130.0, 129.0, 128.9, 128.7, 128.6 (C6H5), 68.0 
(OCH2), 31.9 (OCH2CH2), 29.6, 29.4, 29.3, 26.2, 22.8 (5 CH2), 20.9 
(OCH3), 14.2 (CH3). HRMS: Calcd for C36H46O12F2Na [M+Na]
+ 
731.2849; found 731.2847. 
Octyl 5-O-acetyl-2,3-di-O-benzoyl-6-deoxy-6-fluoro-β-D-
galactofuranosyl-(1→3)-[5-O-acetyl-2,3-di-O-benzoyl-6-deoxy-6-
fluoro-β-D-galactofuranosyl-(1→2)]-6-deoxy-6-fluoro-α-D-
galactopyranoside (13): Trisaccharide 13 was obtained according to 
procedure B (table 1, entries 3, 4) and isolated as a white solid. 
Rf=0.6 (CHex/AcOEt, 6:4); NMR data in tables 4 and 5. 1H NMR 
(CDCl3): 8.09-7.98 (m, 4H, Harom), 7.96-7.88 (m, 3H, Harom ), 7.61-7.55 
(m, 4H, Harom), 7.55-7.40 (m, 5H, Harom), 7.39-7.30 (m, 4H, Harom) 
3.70 (dt, 2J=9.5 Hz, 3J=7.0 Hz, 1H, OCH2), 3.43 (dt, 
2J=9.7 Hz, 3J=6.7 
Hz, 1H, OCH2), 2.08 (s, 3H, OCH3), 2.02 (s, 3H, OCH3), 1.62-1.50 (m, 
2H, OCH2CH2), 1.32-1.13 (m, 10H, 5 CH2), 0.86 (t,
3J=6.7 Hz, 3H, CH3); 
13C NMR (CDCl3): 170.2 (CO), 170.1 (CO), 166.7 (CO), 166.5 (CO), 
166.4 (CO), 166.3 (CO), 133.9, 133.7, 133.6, 133.5, 130.2, 130.0, 
130.0, 129.9, 129.2, 129.1, 129.1, 128.9, 128.8, 128.6, 128.5, 128.4 
(C6H5), 68.9 (OCH2), 32.0 (OCH2CH2), 29.7, 29.5, 29.3, 26.3, 22.8 (5 
CH2), 20.9 , 20.9 (OCH3), 14.2 (CH3). HRMS: Calcd for C58H65O19F3Na 
[M+Na]+ 1145.3970; found 1145.3971. 
Octyl 5-O-acetyl-2,3-di-O-benzoyl-6-deoxy-6-fluoro-β-D-
galactofuranosyl-(1→3)-6-deoxy-6-fluoro-α-D-galactopyranoside 
(14): Compound 14 was obtained according to procedure B (table 1, 
entry 4) and isolated as a white solid. Rf=0.5 (CHex/AcOEt, 6:4); 
NMR data in tables 4 and 5. 1H NMR (CDCl3): 8.11-7.98 (m, 4H, 
Harom), 7.63-7.52 (m, 2H, Harom), 7.49-7.41 (m, 4H, Harom), 3.75 (dt, 
2J=9.8 Hz, 3J=7.0 Hz, 1H, OCH2), 3.50 (dt, 
2J=9.7 Hz, 3J=6.6 Hz, 1H, 
OCH2), 2.08 (s, 3H, OCH3), 1.67-1.60 (m, 2H, OCH2CH2), 1.38-1.10 
(m, 10H, 5 CH2), 0.88 (t,
3J=7.0 Hz, 3H, CH3); 
13C NMR (CDCl3): 170.1 
(CO), 166.7 (CO), 166.6 (CO), 134.0, 133.9, 130.1, 130.0, 128.9, 
128.8, 128.8, 128.7 (C6H5), 68.7 (OCH2), 32.0 (OCH2CH2), 29.6, 29.5, 
29.4, 26.3, 20.9 (5 CH2), 20.9 (OCH3), 14.2 (CH3). HRMS: Calcd for 
C36H46O12F2Na [M+Na]
+ 731.2849; found 731.2853. 
Trifuranoside (15): Trisaccharide 15 was obtained according to 
procedure B (table 1, entries 5, 6) and isolated as a white solid. 
Rf=0.6 (CHex-AcOEt, 6-4). HRMS: Calcd for C58H65O19F3Na [M+Na]
+ 
1145.3964; found 1145.3969. 
Octyl 2,3,5,6-tetra-O-benzoyl-β-D-galactofuranosyl-(1→2)-6-
deoxy-6-fluoro-α-D-galactopyranoside (17): Disaccharide 17 was 
obtained according to procedure A (table 2, entry 1) and isolated as 
a white solid. Rf=0.2 (CHex/AcOEt, 6:4); NMR data in tables 4 and 5. 
1H NMR (CDCl3): 8.10-7.91 (m, 8H, Harom), 7.59-7.49 (m, 4H, Harom), 
7.43-7.29 (m, 8H, Harom), 3.68 (dt, 
2J=9.7 Hz, 3J=6.9 Hz, 1H, OCH2), 
3.44 (dt, 2J=9.7 Hz, 3J=6.6 Hz, 1H, OCH2), 1.57-1.49 (m, 2H, 
OCH2CH2), 1.32-1.13 (m, 10H, 5 CH2), 0.85 (t,
3J=6.3 Hz, 3H, CH3); 
13C 
NMR (CDCl3): 166.5 (CO), 166.2 (CO), 165.7 (CO), 165.7 (CO), 133.9, 
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133.7, 133.5, 133.3, 130.1, 130.1, 130.0, 129.9, 129.6, 129.5, 129.0, 
128.7, 128.6, 128.6, 128.5 (C6H5), 68.9 (OCH2), 32.0 (OCH2CH2), 29.8, 
29.5, 29.3, 26.3, 22.8 (5 CH2), 14.2 (CH3). HRMS: Calcd for 
C48H53O14FNa [M+Na]
+ 895.3312; found 895.3315. 
 
2,3,5,6-tetra-O-benzoyl-α,β-D-galactofuranose (18): Compound 18 
was obtained according to procedure A (table 2, entries 2, 3) and 
isolated as a white solid. Rf=0.6 (CHex/AcOEt, 6:4); 1H NMR (CDCl3): 
8.11-7.88 (m, 8H, Harom), 7.58-7.46 (m, 4H, Harom), 7.44-7.27 (m, 8H, 
Harom), 6.10 (t, J2α-3α=5.1 Hz, 0.3H, H-3α), 6.06 (dt, J4β-5β=7.0 Hz, J5β-
6β=3.1 Hz, 0.7H, H-5β), 5.98 (td, J4α-5α=6.3 Hz, J5α-6α=3.6 Hz, 0.3H, H-
5α), 5.85 (d, J1α-2α=4.5 Hz, 0.3H, H-1α), 5.72 (s, 0.7H, H-1β), 5.66 
(ddd, J3β-4β=5.0 Hz, J2β-3β=1.4 Hz, J1β-3β=0.7 Hz, 0.7H, H-3β), 5.56 (dd, 
J2α-3α=5.4 Hz, J1α-2α=4.4 Hz, 0.3H, H-2α), 5.52 (dd, J2β-3β=1.4 Hz, J1β-
2β=0.6 Hz, 0.7H, H-2β), 4.87 (dd, J3β-4β=5.0 Hz, J4β-5β=4.0 Hz, 0.7H, H-
4β), 4.82-4.68 (m, 2H, H-6α, H-6β), 4.56 (dd, J4β-5β=6.6 Hz, J3α-4α=4.7 
Hz, 0.3H, H-4α); 13C NMR (CDCl3): 166.4 (CO), 166.2 (CO), 166.2 
(CO), 165.9 5CO), 165.8 (CO), 165.8 (CO), 165.7 (CO), 165.6 (CO), 
133.7, 133.6, 133.5, 133.4, 133.2, 130.1, 130.0, 129.8, 129.8, 129.5, 
129.6, 129.6, 129.1, 128.9, 128.6, 128.6, 128.5, 128.5, 128.5, 128.4 
(C6H5), 101.2 (C-1β), 96.2 (C-1α), 82.8 (C-2β), 81.8 (C-4β), 79.5 (C-
4α), 77.8 (C-3β), 77.7 (C-2α), 76.0 (C-3α), 72.4 (C-5α), 70.7 (C-5β), 
63.7 (C-6β), 63.3 (C-6α); HRMS : Calcd for C34 H28 O10 Na [M+Na]
+ 
619.1575; found 619.1576. 
 
Octyl 2,3,5,6-tetra-O-benzoyl-β-D-galactofuranoside (19): 
Monosaccharide 19 was obtained according to procedure A (table 
2, entries 1-3) as a white solid. Rf=0.7 (CHex/AcOEt, 6:4); 1H NMR 
(CDCl3): 8.11-7.89 (m, 8H, Harom), 7.60-7.49 (m, 4H, Harom), 7.45-7.27 
(m, 8H, Harom), 6.08 (ddd, J5,6a=7.0 Hz, J5,6b=4.6 Hz, J4,5=3.5 Hz 1H, H-
5), 5.64 (td, J3,4=5.2 Hz, J2,3=0.9 Hz, 1H, H-3), 5.47 (d, J2,3=1.1 Hz, 1H, 
H-2), 5.31 (s, 1H, H-1), 4.82-4.71 (m, 2H, H-6), 4.65 (dd, J3,4=5.2 Hz, 
J4,5=3.5 Hz, 1H, H-4), 3.75 (dt, 
2J=9.5 Hz, 3J=6.3 Hz, 1H, OCH2), 3.54 
(dt, 2J=9.5 Hz, 3J=6.3 Hz, 1H, OCH2), 1.71-1.67 (m, 2H, OCH2CH2), 
1.41-1.18 (m, 10H, 5 CH2), 0.87 (t, 
2J=6.3 Hz, 3H, CH3); 
13C NMR 
(CDCl3): 165.9 (CO), 165.6 (CO), 165.5 (CO), 165.3 (CO), 133.2, 
133.1, 133.0, 132.9, 129.9, 129.8, 129.7, 129.5, 129.4, 129.3, 128.9, 
128.8 (C6H5), 105.4, (C-1), 81,9 (C-2), 81.0 (C-4), 77.4 (C-3), 70.1 (C-
5), 67.5 (OCH2), 63.3 (C-6), 31.6 (OCH2CH2), 29.3, 29.2, 29.1, 26.0, 
22.5 (5 CH2), 13.9 (CH3); HRMS : Calcd for C42 H44 O10 Na [M+Na]
+ 
731.2827; found 731.2829. 
 
Octyl 2,3,5,6-tetra-O-benzoyl-β-D-galactofuranosyl-(1→2)-6-
deoxy-6-fluoro-β-D-galactofuranoside (20): Disaccharide 20 was 
obtained according to procedure A (table 2, entries 2 and 3) and 
procedure B (table 2, entry 4) and isolated as a white solid. Rf=0.6 
(CHex/AcOEt, 6:4); NMR data in tables 4 and 5; 1H NMR (CDCl3): 
8.12-7.96 (m, 6H, Harom), 7.91-7.84 (m, 2H, Harom), 7.60-7.48 (m, 4H, 
Harom), 7.46-7.23 (m, 8H, Harom), 3.70-3.60 (m, 1H, OCH2), 3.45-3.31 
(m, 1H, OCH2), 1.58-1.49 (m, 2H, OCH2CH2), 1.33-1.19 (m, 10H, 5 
CH2), 0.91-0.83 (m, 3H, CH3); 
13C NMR (CDCl3): 166.4-165.5 (CO), 
133.8-128.3 (C6H5), 68.0 (OCH2), 321.9 (OCH2CH2), 29.6-22.8 (5 CH2), 
14.2 (CH3). HRMS: Calcd for C48H53O14FNa [M+Na]
+ 895.3312; found 
895.3315. 
 
Octyl 2,3,5,6-tetra-O-benzoyl-β-D-galactofuranosyl-(1→3)-6-
deoxy-6-fluoro-β-D-galactofuranoside (21): Disaccharide 21 was 
obtained according to procedure A (table 2, entries 2, 3) and 
procedure B (table 2, entry 4) and isolated as a white solid. Rf=0.6 
(CHex/AcOEt, 6:4); NMR data in tables 4 and 5; 1H NMR (CDCl3): 
8.12-7.96 (m, 6H, Harom), 7.91-7.84 (m, 2H, Harom), 7.60-7.48 (m, 4H, 
Harom), 7.46-7.23 (m, 8H, Harom), 3.70-3.60 (m, 1H, OCH2), 3.45-3.31 
(m, 1H, OCH2), 1.58-1.49 (m, 2H, OCH2CH2), 1.33-1.19 (m, 10H, 5 
CH2), 0.91-0.83 (m, 3H, CH3); 
13C NMR (CDCl3): 166.4-165.5 (CO), 
133.8-128.3 (C6H5), 68.0 (OCH2), 321.9 (OCH2CH2), 29.6-22.8 (5 CH2), 
14.2 (CH3). HRMS: Calcd for C48H53O14FNa [M+Na]
+ 895.3312; found 
895.3314. 
 
Octyl 2,3,5,6-tetra-O-benzoyl-β-D-galactofuranosyl-(1→5)-6-
deoxy-6-fluoro-β-D-galactofuranoside (22): Disaccharide 22 was 
obtained according to procedure A (table 2, entries 2 and 3) and 
procedure B (table 2, entry 4) and isolated as a white solid. Rf=0.6 
(CHex/AcOEt, 6:4); NMR data in tables 4 and 5; 1H NMR (CDCl3): 
8.12-7.96 (m, 6H, Harom), 7.91-7.84 (m, 2H, Harom), 7.60-7.48 (m, 4H, 
Harom), 7.46-7.23 (m, 8H, Harom), 3.70-3.60 (m, 1H, OCH2), 3.45-3.31 
(m, 1H, OCH2), 1.58-1.49 (m, 2H, OCH2CH2), 1.33-1.19 (m, 10H, 5 
CH2), 0.91-0.83 (m, 3H, CH3); 
13C NMR (CDCl3): 166.4-165.5 (CO), 
133.8-128.3 (C6H5), 68.0 (OCH2), 321.9 (OCH2CH2), 29.6-22.8 (5 CH2), 
14.2 (CH3). HRMS: Calcd for C48H53O14FNa [M+Na]
+ 895.33116; 
found 895.3314. 
Trifuranoside (23): Trisaccharide 23 was obtained according to 
procedure B (table 2, entry 4) and isolated as a white solid. Rf=0.6 
(CHex/AcOEt, 6:4); NMR data in tables 4 and 5. HRMS: Calcd for 
C82H79O23FNa [M+Na]
+ 1473.4888; found 1473.4891. 
 
General proedure for deacylation reaction (C): To a solution of the 
protected carbohydrate in dry CH2Cl2/MeOH (1/1) (0.07 M) was 
added MeONa 5.4M (0.2 equiv). The mixture was stirred for 24h at 
room temperature. Then the solution was neutralized by the 
addition of IR 120-H+ form resin. After filtration, the filtrate was 
evaporated under reduced pressure. The residual solid was 
suspended in water and freeze dried in order to co evaporate 
methyl esters. 
 
Octyl 6-deoxy-6-fluoro-β-D-galactofuranosyl-(1→2)-6-deoxy-6-
fluoro-β-D-galactofuranoside (24): Disaccharide 24 was obtained 
according to procedure C and isolated as a white solid (6 mg, 95%). 
1H NMR (CD3OD): 5.08 (d, J1,2=1.9 Hz, 1H, H-1b), 4.98 (d, J1,2=1.6 Hz, 
1H, H-1a), 4.58-4.48 (m, 2H, H-6a, H-6b), 4.46-4.35 (m, 2H, H-6a, H-
6b), 4.17 (dd, J3,4=7.7 Hz, J2,3=4.1 Hz, 1H, H-3a), 4.07 (dd, J3,4=6.3 Hz, 
J2,3=3.9 Hz, 1H, H-3b), 4.00 (dd, J2,3=3.9 Hz, J1,2=1.9 Hz, 1H, H-2b), 
3.99 (dd, J2,3=4.1 Hz, J1,2=1.6 Hz, 1H, H-2a), 3.97-3.90 (m, 3H, H-4b, 
H-5b, H-5a), 3.85 (dd, J3,4=7.7 Hz, J4,5=3.2 Hz, 1H, H-4a), 3.68 (dt, 
2J=9.6 Hz, 3J=6.7 Hz, 1H, OCH2), 3.43 (dt, 
2J=9.6 Hz, 3J=6.5 Hz, 1H, 
OCH2), 1.64-4.55 (m, 2H, OCH2CH2),1.41-1.25 (m, 10H, 5 CH2), 0.91 
(t, 3J=6.3 Hz, 3H, CH3); 
13C NMR (CD3OD): 109.8 (C-1b), 108.0 (C-1a), 
90.6 (C-2a), 85.2 (d, JC-F=171.2 Hz, C-6b), 85.1 (d, JC-F=169.9, C-6a), 
83.6 (d, JC-F=4.3 Hz, C-4b), 83. (C-2b), 81.8 (d, JC-F=7.3 Hz, C-4a), 78.3 
(C-3b), 77.2 (C-3a), 69.8 (d, JC-F=20.0 Hz, C-5a, C-5b), 68.9 (OCH2), 
33.0, 30.8, 30.5, 30.4, 27.3, 23.7 (6 CH2), 14.4 (CH3). HRMS: Calcd for 
C20H36O10F2Na [M+Na]
+ 481,2220; found 481.2222. 
 
Octyl 6-deoxy-6-fluoro-β-D-galactofuranosyl-(1→3)-6-deoxy-6-
fluoro-β-D-galactofuranoside (25): Disaccharide 25 was obtained 
according to procedure C and isolated as a white solid (8 mg, 88%). 
1H NMR (CD3OD): 5.06 (d, J1,2=2.0 Hz, 1H, H-1b), 4.86 (d, J1,2=1.6 Hz, 
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1H, H-1a), 4.56-4.46 (m, 2H, H-6a, H-6b), 4.43-4.34 (m, 2H, H-6a, H-
6b), 4.15-4.10 (m, 1H, H-3a), 4.08 (dd, J2,3=3.2 Hz, J1,2=1.6 Hz, 1H, H-
2a), 4.06-3.99 (m, 3H, H-3b, H-4a, H-5b), 4.00 (d, J1,2=2.1 Hz, 1H, H-
2b), 3.98-3.89 (m, 2H, H-4b, H-5a), 3.65 (dt, 2J=9.7 Hz, 3J=6.7 Hz, 1H, 
OCH2), 3.41 (dt, 
2J=9.7 Hz, 3J=6.4 Hz, 1H, OCH2), 1.64-4.52 (m, 2H, 
OCH2CH2), 1.49-1.23 (m, 10H, 5 CH2), 0.89 (t, J=7.4 Hz, 3H, CH3); 
13C 
NMR (CD3OD): 109.3 (C-1a), 109.1 (C-1b), 85.2 (d, JC-F=169.6 Hz, C-
6a), 85.0 (d, JC-F=170.7 Hz, C-6b), 84.2 (C-3a), 83.5 (d, JC-F=6.3 Hz, C-
4b), 83.0 (C-2b), 82.1 (d, JC-F=6.6 Hz, H-4a), 81.6 (C-2a), 78.0 (C-3b), 
67.8 (d, JC-F=18.3 Hz, C-5b), 69.7 (d, JC-F=20.2 Hz, C-5a), 68.7 (OCH2), 
32.8, 30.5, 30.3, 30.2, 27.0, 23.5, (6 CH2), 14.4 (CH3). HRMS: Calcd 
for C20H36O10F2Na [M+Na]
+ 481,2220; found 481.2220. 
Octyl 6-deoxy-6-fluoro-β-D-galactofuranosyl-(1→5)-6-deoxy-6-
fluoro-β-D-galactofuranoside (26): Disaccharide 26 was obtained 
according to procedure C and isolated as a white solid (6 mg, 93%). 
1H NMR (CD3OD): 5.17 (s, 1H, H-1b), 4.83 (d, J1,2=1.7 Hz, H-1a), 4.70-
4.61 (m, 1H, H-6a), 4.61-4.46 (m, 2H, H-6a, H-6b), 4.46-4.41 (m, 1H, 
H-6a), 4.21-4.10 (m, 1H, H-5a), 4.13 (dd, J3,4=4.5 Hz, J4,5=3.4 Hz, 1H, 
H-4b), 4.05-3.98 (m, 3H, H-3a, H-3b, H-5b), 3.97-3.90 (m, 3H, H-2a, 
H-4a, H-2b), 3.69-3.60 (m, 1H, OCH2), 3.46-3.36 (m, 1H, OCH2), 1.61-
1.50 (m, 2H, OCH2CH2), 1.38-1.20 (m, 10H, 5 CH2), 0.87 (t, 
3J=5.4 Hz, 
3H, CH3); 
13C NMR (CD3OD): 109.1 (C-1a, C-1b), 85.2 (d, JC-F=6.4 Hz, 
C-4b), 85.1 (d, JC-F=167.5 Hz, C-6b), 84.1 (d, JC-F=168.9 Hz, C-6a), 83.0 
(C-2a, C-2b), 82.9 (d, JC-F=7.2 Hz, C-4a), 78.2 (C-3a), 77.6 (C-3b), 74.6 
(d, JC-F=17.5 Hz, C-5a), 70.5 (d, JC-F=19.9 Hz, C-5b), 69.9 (OCH2), 32.7, 
30.3, 30.2, 30.1, 26.9, 23.4 (6 CH2), 14.4 (CH3); HRMS : Calcd for 
C20H36O10F2Na [M+Na]
+ 481.2220; found 481.2220. 
Octyl 6-deoxy-6-fluoro-β-D-galactopyranosyl-(1→2)-6-deoxy-6-
fluoro-β-D-galactofuranoside (27): Disaccharide 27 was obtained 
according to procedure C and isolated as a white solid (4 mg, 92%). 
1H NMR (CD3OD): 5.06 (d, J1,2=1.7 Hz, 1H, H-1b), 4.99 (d, J1,2=3.8 Hz, 
1H, H-1a), 4.65-4.35 (m, 4H, H-6a, H-6b), 4.08 (dd, J2,3=3.8 Hz, 
J1,2=1.8 Hz, 1H, H-2b), 4.03-4.01 (m, 1H, H-5b), 4.01-3.92 (m, 1H, H-
5a), 3.99 (dd, J2,3=3.8 Hz, J2,3=3.1 Hz, 1H, H-3b), 3.97 (dd, J3,4=3.1 Hz, 
J4,5=2.1 Hz, 1H, H-4b), 3.92 (dd, J3,4=3.4 Hz, J4,5=1.3 Hz, 1H, H-4a), 
3.87 (dd, J2,3=10.0 Hz, J3,4=3.4 Hz, 1H, H-3a), 3.77 (dd, J2,3=10.0 Hz, 
J1,2=3.7 Hz, 1H, H-2a), 3.69 (dt, 
2J=9.6 Hz, 3J=6.9 Hz, 1H, OCH2), 3.45 
(dt, 2J=9.6 Hz, 3J=6.4 Hz, 1H, OCH2), 1.67-1.56 (m, 2H, OCH2CH2), 
1.43-1.28 (10H, 5 CH2), 0.91 (t, 
3J=6.7 Hz, 3H, CH3); 
13C NMR (CDCl3): 
110.9 (C-1b), 99.7 (C-1a), 84.3 (d, JC-F=170.6 Hz, C-6a), 84.0 (d, JC-
F=5.6 Hz, C-4b), 83.6 (d, JC-F=167.2 Hz, C-6b), 81.8 (C-2b), 77.9 (C-
3b), 77.6 (C-2a), 70.2 (d, JC-F=21 Hz, H-5b), 70.2 (d, JC-F=6.2 Hz, C-4a), 
69.6 (d, JC-F=16.9 Hz, C-5a), 69.5 (C-3a), 69.1 (OCH2), 32.7, 30.3, 
30.2, 30.1, 23.4 (5 CH2), 14.4 (CH3). HRMS: Calcd for C20H36O10F2 Na 
[M+Na]+ 481.2220; found 481.2213. 
Disaccharides 28, 29 and 30 were deacylated according to 
procedure C. Purification gave a mixture of the three compounds 
(15 mg, 90%, ratio 30:26:44 for 25/26/27). NMR assignement for 
each disachcharide yielded to the following data: HRMS : Calcd for 
C20H37O10FNa [M+Na]
+ 479.2263; found 479.2262; Octyl β-D-
galactofuranosyl-(1→2)-6-deoxy-6-fluoro-β-D-galactofuranoside 
(28): 1H NMR (CD3OD): 5.07 (d, J1,2=1.6 Hz, H-1b), 4.99 (d, J1,2=1.4 
Hz, H-1a), 4.54-4.47 (m, 1H, H-6a), 4.41-4.34 (m, 1H, H-6a), 4.13 (dd, 
J3,4=3.5 Hz, J2,3=1.6 Hz, H-3a), 4.05-4.02(m, 1H, H-3b), 4.01-3.96 (m, 
2H, H-2a, H-2b), 3.96-3.92 (m, 2H, H-5a, H-4b), 3.86 (dd, J4,5=7.3 Hz, 
J3,4=3.1 Hz, H-4a), 3.76-3.70 (m, 1H, H-5b), 3.68-3.58 (m, 3H, H-6b, 
OCH2), 3.45-3.35 (m, 1H, OCH2), 1.60-1.50 (m, 2H, OCH2CH2), 1.37-
1.19 (m, 10H, 5 CH2), 0.86 (t, 
3J=6.7 Hz, 3H, CH3); 
13C NMR (CD3OD): 
108.0 (C-1b), 106.5 (C-1a), 88.5 (C-2a), 84.1 (d, JC-F=169.2 Hz, C-6a), 
83.9 (C-3b), 81.5 (C-2b), 80.9 (d, JC-F=6.2 Hz, C-4a), 77.3 (C-3b), 75.7 
(C-3a), 71.0 (C-5b), 68.5 (d, JC-F=19.9 Hz, C-5a), 67.9 (OCH2), 63.4 (C-
6b), 31.7, 29.4, 29.2, 29.1, 25.9, 22.4 (5 CH2), 13.5 (CH3); Octyl β-D-
galactofuranosyl-(1→3)-6-deoxy-6-fluoro-β-D-galactofuranoside 
(29): 1H NMR (CD3OD): 5.07 (d, J1,2=1.6 Hz, H-1b), 4.86 (d, J1,2=1.6 
Hz, H-1a), 4.54-4.47 (m, 1H, H-6a), 4.41-4.34 (m, 1H, H-6a), 4.17-
4.13 (m, 1H, H-3a), 4.07 (dd, J2,3=3.2 Hz, J1,2=1.6 Hz, H-2a), 4.09-4.05 
(m, 1H, H-5a), 4.03-3.98 (m, 3H, H-4a, H-2b, H-3b), 3.98-3.92 (m, 
1H, H-4b), 3.76-3.70 (m, 1H, H-5b), 3.68-3.58 (m, 3H, H-6b, OCH2), 
3.45-3.35 (m, 1H, OCH2), 1.60-1.50 (m, 2H, OCH2CH2), 1.37-1.19 (m, 
10H, 5 CH2), 0.86 (t, 
3J=6.7 Hz, 3H, CH3); 13C NMR (CD3OD): 108.1 (C-
1a), 107.6 (C-1b), 84.1 (d, JC-F=169.2 Hz, C-6a), 83.9 (C-4b), 82.4 (C-
3a), 81.5 (C-2b), 80.9 (d, JC-F=6.6 Hz, C-4a), 80.1 (C-2a), 77.3 (C-3b), 
70.9 (C-5b), 68.3 (d, JC-F=19.7 Hz, C-5a), 67.8 (OCH2), 63.1 (C-6b), 
31.7, 29.4, 29.2, 29.1, 25.9, 22.4 (5 CH2), 13.5 (CH3); Octyl β-D-
galactofuranosyl-(1→5)-6-deoxy-6-fluoro-β-D-galactofuranoside 
(30): 1H NMR (CD3OD): 5.16 (s, 1H, H-1b), 4.83 (d, J1,2=1.7 Hz, H-1a), 
4.66-4.63 (m, 1H, H-6a), 4.54-4.47 (m, 1H, H-6a), 4.20-4.12 (m, 2H, 
H-4b, H-5a), 4.05-3.98 (m, 3H, H-2b, H-3b, H-3a), 3.96-3.92 (m, 2H, 
H-2a, H-4a), 3.76-3.70 (m, 1H, H-5b), 3.68-3.58 (m, 3H, H-6b, OCH2), 
3.45-3.35 (m, 1H, OCH2), 1.60-1.50 (m, 2H, OCH2CH2), 1.37-1.19 (m, 
10H, 5 CH2), 0.86 (t, 
3J=6.7 Hz, 3H, CH3); 13C NMR (CD3OD): 108.0 (C-
1a), 107.8 (d, JC-F=2.4 Hz, C-1b), 84.4 (C-4b), 83.6 (d, JC-F=170.1 Hz, C-
6a), 81.9 (C-2a), 81.7 (d, JC-F=7.2 Hz, C-4a), 80.8 (C-2b), 77.8 (C-3b), 
77.3 (C-3a), 73.2 (d, JC-F=18.6 Hz, C-5a), 71.0 (C-5b), 68.9 (OCH2), 
62.8 (C-6b), 31.7, 29.4, 29.2, 29.1, 25.9, 22.4 (5 CH2), 13.5 (CH3). 
Computational details: All DFT calculations were carried out with 
the Gaussian16 (version A.03) program,50 tightening self-consistent 
field convergence thresholds (10-10 au). For all calculations, the 
hybrid B3LYP functional51, 52 has been used. The 6-311G(2d,p) 
atomic basis set has been employed for geometry and frequency 
calculations. Solvent effects (solvent=acetonitrile) were included 
according to the Polarizable Continuum Model.53 Fukui and 
condensed Fukui functions54 have been calculated via Finite 
Difference method and are given for various atomic charges 
(Mulliken, Hirshfeld, Voronoi, Bader). 
Microtiter test based evaluation of minimum inhibitory 
concentration (MIC) against Leishmania tarentolae:55 
Preparation of Leishmania tarentolae cultures: Amplification of 
Leishmania tarentolae (ATCC®30267) in its promastigote phase was 
carried out by culture in modified M199 medium supplemented 
with 10% inactivated fetal calf serum, 40 µM HEPES, 100 μM 
adenine, 5 μM hemin, 1 μM biotin, 3 μM biopterin and 1 µM 
penicillin/streptomycin pH 7.4 at 27 °C for 6 days, until they 
reached stationary phase. 
Preparation of different concentrations of octyl glycofuranosides: 
Different amounts of octyl glycofuranosides were dissolved in M199 
medium supplemented as above in order to obtain a total volume 
of 1 mL with the following concentrations in furanosides: 0, 50, 100, 
250, 500 and 750 µmol.L-1. Each tube was then supplemented with 
10 μL of the L. tarentolae culture. In parallel, an equal number of 
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tubes without inoculum was prepared to serve as blanks. All 
samples were finally incubated for 3 days at 27 °C. 
Determination of MICs: A 50 μL aliquot from a 0.0125% (w/v) 
solution of resazurin (1.25 mg of resazurin in 10 mL of a 0.1 M 
phosphate buffer saline solution) was added to each sample after 
filtration (0.2 µm). After developing for 4 h at 37 °C and 100 rpm, 
each sample (400 µL) was centrifuged (5000 rpm, 5 min). The 
supernatant (200 μL) was then pipetted and added to the identified 
wells of a 96-well microplate. The plate had a set of controls: a 
column with octyl galactofuranoside as a positive control (in serial 
dilution), a column with all solutions with the exception of the test 
compound, and a column with all solutions with the exception of L. 
tarentolae. The absorbance of each well at 602 nm was then 
measured in 96-wellmicrotiter plate reader. The MIC of the sample 
without bacterial inoculum was then calculated as the 
concentration where 99% of the bacteria growth is inhibited. 
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 Table 4 1H NMR (CDCl3) data [δ (J, Hz)]. 
 Unit c       Unit b       Unit a       
 H-1 H-2 H-3 H-4 H-5 H-6 H-6’ H-1 H-2 H-3 H-4 H-5 H-6 H-6’ H-1 H-2 H-3 H-4 H-5 H-6 H-6’ 
7        5.37 
(1.0) 
5.46 
(3.3) 
5.60 
(7.0) 
4.72-
4.48 
5.45-
5.37 
4.72-4.48 5.07 
(3.6) 
3.89 
(9.0) 
4.16-
4.06 
4.16-
4.06 
4.16-
4.06 
4.72-4.48 
8β               5.65 
(<1) 
5.61-5.45 4.69 
(4.7) 
5.61-
5.45 
4.67 (1.7, 5.1, 
46.7) 
9               5.25 
(<1) 
5.47-5.43 4.49 
(4.5) 
5.57 
(16.9, 
5.0) 
4.64 
(5.0, 
10.0, 
46.6) 
4.70 
(5.8, 
10.0, 
46.6) 
10        5.46 
(<1) 
5.42 
(1.5) 
5.50 
(5.0) 
4.53 
(4.8) 
5.58-
5.53 
4.64 
(5.1, 
9.6, 
46.4) 
4.70 
(5.4, 
9.7, 
46.6) 
5.14 
(0.7) 
4.17 
(1.9) 
4.24 
(3.9, 
10.1) 
4.13-
4.10 
4.09-
4.02 
4.51 (5.4, 46.8) 
11        5.45 
(<1) 
5.46 5.53-
5.47 
4.50 
(4.8) 
5.53-
5.47 
4.78-4.53 4.97 
(1.1) 
4.28 
(ls) 
4.24 
(2.3, 
4.9) 
4.17-4.12 4.50 (5.4, 47.4) 
12        5.56 
(<1) 
5.53-5.48 4.75 
(4.9) 
5.53-
5.48 
4.82-4.56 4.94 
(<1) 
4.08-
4.02 
4.00-
3.94 
4.15 
(2.7, 
3.8) 
4.33 
(2.7, 
4.4, 
7.1, 
14.0) 
4.82-4.56 
13 5.53 4.49-
4.47 
5.44 
(5.4, 
1.3) 
4.55-
4.50 
5.57-
5.50 
4.75-4.55 5.81 5.58 
(1.2) 
5.49-
5.47 
4.55-
4.50 
5.57-
5.50 
4.75-4.55 
 
5.03 
(3.7) 
4.12 
(3.4) 
4.26 
(9.9) 
4.12-4.07 4.75-4.55 
14        5.68 
(0.6) 
5.58 
(2.2) 
5.54 
(5.2) 
4.49 5.50-
5.42 
4.80-4.50 4.97 
(3.7) 
4.16-
4.02 
3.96 
(3.3, 
9.7) 
4.16-4.02 4.80-4.50 
17        5.46 
(<1) 
5.48 
(2.5) 
5.75 
(6.2) 
4.75 5.97 
(6.8, 
4.1) 
4.78-4.64 5.07 
(3.6) 
3.95 
(9.6) 
4.16-4.03 4.69-4.56 
18α               5.85 
(4.5) 
5.56 
(5.4) 
6.10 
(5.1) 
4.56 
(6.7) 
5.98 
(3.6) 
4.82-4.68 
18β               5.72 
(<1) 
5.52 
(1.4) 
5.66 
(5.0) 
4.87 
(4.0) 
6.14-
6.04 
4.82-4.68 
19               5.33 5.49 
(1.0) 
5.65 
(5.2) 
4.67 
(3.5) 
6.10 
(7.0, 
4.83-4.71 
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4.6) 
20        5.52 5.43 
(1.3) 
5.68 
(5.3) 
4.71-
4.67 
6.08-
5.99 
4.84-4.67 5.18 
(<1) 
4.19 
(2.0) 
4.32-
4.27 
4.12-4.09 4.44-4.42 
4.57-4.53 
21        5.54 5.48 
(1.4) 
5.66-
5.64 
4.67-
4.60 
6.08-
5.99 
4.84-4.67 4.98 4.37-
4.23 
4.31-
4.27 
4.20-
4.17 
4.12-
4.09 
4.43-4.38 
4.54-4.50 
22        5.61 5.41 
(1.4) 
5.65 
(5.2) 
4.99-
4.95 
6.08-
5.99 
4.84-4.67 4.95 3.95 4.12-
4.09 
4.15 4.34-
4.23 
4.84-4.69 
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Table 5. 13C NMR data [δ (JC-F, Hz)]. 
Unit c Unit b Unit a 
C-1 C-2 C-3 C-4 C-5 C-6 C-1 C-2 C-3 C-4 C-5 C-6 C-1 C-2 C-3 C-4 C-5 C-6 
7 108.3 83.6 75.9 78.6 
(6.3) 
68.8 
(21.1) 
80.5 (173.9) 98.5 78.3 68.6 68.9 
(4.9) 
68.5 
(24.3) 
83.2 
(164.5) 
8β 101.1 82.4 77.4 80.8 
(3.2) 
70.6 
(20.7) 
81.4 
(176.3) 
9 106.7 82.0 77.3 80.2 
(5.7) 
70.4 
(20.7) 
81.1 
(173.2) 
10 105.7 82.2 76.2 80.9 
(4.6) 
70.1 
(21.1) 
80.8 (173.6) 106.1 86.1 76.2 84.7 
(5.2) 
69.7 
(20.6) 
83.7 
(170.7) 
11 106.2 82.1 76.9 80.7 
(5.2) 
70.1 
(20.9) 
80.7 (173.9) 108.4 79.8 84.3 81.5 
(6.2) 
69.4 
(19.9) 
84.3 
(169.9) 
12 106.4 
(5.6) 
82.0 77.1 81.0 
(7.9) 
70.2 
(21.1) 
81.3 (172.8) 107.9 79.0 78.4 85.2 
(3.9) 
75.6 
(19.0) 
83.6 
(170.8) 
13 107.6 82.3 77.2 81.7 
(5.0) 
70.3 
(20.5) 
81.1 or 80.6 
(173.4) 
107.2 81.4 77.2 80.3 
(4.4) 
70.3 
(20.5) 
80.6 or 81.1 
(173.4) 
98.7 75.4 74.9 69.7 
(6.4) 
68.0 
(22.5) 
88.6 
(168.9) 
14 107.3 82.3 76.8 80.7 
(5.0) 
70.1 
(20.2) 
80.8 (173.6) 98.5 68.5 78.0 69.2 
(6.5) 
68.6 
(21.0) 
82.5 
(167.5) 
17 108.5 83.6 76.8 80.8 70.3 63.5 98.5 78.2 68.4 68.7 
(5.6) 
68.4 
(22.8) 
82.9 
(167.1) 
18α 96.2 77.7 76.0 79.5 72.4 63.3 
18β 101.2 82.8 77.8 81.8 70.7 63.7 
19 106.4 81.9 77.4 81.0 70.1 63.3 
20 105.9 82.6 77.5 82.1 70.3 63.3 106.0 86.2 76.2 84.6 
(6.7) 
69.7 
(20.9) 
83.7 
(172.6) 
21 105.8 82.3 77.2 82.1 70.5 63.4 108.5 79.7 83.4 81.2 
(5.8) 
69.2 
(20.3) 
84.0 
(169.3) 
22 106.4 
(3.5) 
82.4 77.8 82.5 70.6 63.5 108.0 79.3 78.4 85.1 
(2.7) 
75.3 
(19.2) 
83.6 
(171.4) 
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 Conclusions 
Synthesis of fluor-containing oligofuranosides was performed 
from a C-6-fluorinated and O-2, O-3, O-5 unprotected 
glycofuranoside 2, and four different furanosyl donors. This 
study highlighted the significant impact of the fluorine atom 
on both the donor and the acceptor reactivity. The presence of 
fluorine at C-6 decreased the reactivity of the donor with 
respect to the standard perbenzoylated galactofuranosyl one. 
Moreover, regioselective glycosylation of the fluorinated 
acceptor followed different pathways yielding to (i) the three 
difuranosides (and trisaccharides), (ii) isomers characterized by 
a pyranosyl moiety originated from the starting furanosidic 
acceptor, and (iii) a monofuranoside resulting from the 
transfer of the aglycon from the acceptor to the donor. Best 
results in terms of the desired regioselective glycosylation of 2 
were obtained with the non-fluorinated thiogalactofuranoside 
16b. Interestingly, DFT calculations of Fukui indexes f- helped 
to explain the remained nucleophilicity of O-1, and so the 
transfer of the O-alkyl chain from the fluorinated acceptor to 
the donor. On another hand, the presence of fluorine atoms in 
octyl mono- or digalactofuranosides contributed to the growth 
inhibition of Leishmania tarentolae and MIC values were 
improved by a magnitude of 3-4 compared to the non-
fluorinated GalfOct used as a reference. 
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